TRV250
TRV250 is being developed for the acute treatment of migraine.
Learn MoreTargeted and Innovative CNS Therapies
Trevena is focused on developing and commercializing novel medicines for patients with central nervous system (CNS) disorders.
OLINVYK™ is approved by the FDA. Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. Additional pipeline assets are in development for migraine, opioid use disorder and other CNS indications as well as acute lung injury / acute respiratory distress syndrome (COVID-19). All of the company’s investigational assets have unique mechanisms of action (MOA) that are designed to optimize receptor pharmacology. The result is a pipeline of innovative therapies targeting well-known receptors, but with a potentially more favorable pharmacological profile than current drugs targeting the same receptor class.
| Program | Molecular Target | Therapeutic Target | Current Phase | PC | PH1 | PH2 | PH3 | NDA | Approved |
|---|---|---|---|---|---|---|---|---|---|
| OLINVYK™ (oliceridine) injection | Mu receptor | Acute pain | Approved | PC complete | PH1 complete | PH2 complete | PH3 complete | NDA complete | Approved in progress |
| TRV027 | AT1 receptor | ARDS / abnormal clotting (COVID-19) | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV250 | Delta receptor | Acute migraine | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV734 | Mu receptor | Opioid use disorder | PH1 | PC complete | PH1 in progress | PH2 not started | PH3 not started | NDA not started | Approved not started |
| TRV045 | S1P receptor | CNS disorders | PC | PC in progress | PH1 not started | PH2 not started | PH3 not started | NDA not started | Approved not started |
The pipeline assets are investigational products not approved by FDA for sale or distribution in the U.S.
G Protein-coupled Receptors
G protein-coupled receptors (GPCRs) make up the largest family of transmembrane receptors, with approximately 34% of all U.S. Food and Drug Administration (FDA) approved drugs targeting this receptor class.
Typically, GPCR activation engages broad networks of signaling pathways, which are linked to distinct biological responses. Trevena’s compounds employ a functionally-selective MOA at the receptor site, which enables preferential activation of specific signaling pathways while minimizing activation of others.
Through this approach, the company believes it has developed a set of drug candidates with the potential to engage the signaling pathways responsible for therapeutic effect, with reduced activation of the pathways responsible for adverse effects, thus allowing for a more targeted approach to delivering therapeutic benefit.